NetworkNewsBreaks – Annovis Bio Inc. Advances Al
Post# of 101
(Total Views: 46)
Posted On: 11/11/2024 3:32:57 PM
NetworkNewsBreaks – Annovis Bio Inc. Advances Alzheimer’s Phase 3 Trials with Strong FDA Support and Financial Backing
Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened its intellectual property with new patents for buntanetap combination therapies and expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support trial quality and completion.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Annovis Bio (NYSE: ANVS) provided a third-quarter update, announcing significant progress in developing its lead drug candidate, buntanetap, for Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). Following a successful Phase 2 meeting with the FDA, Annovis received clearance to initiate two Phase 3 studies for AD: a six-month trial to evaluate symptomatic relief and an 18-month trial to assess disease-modifying potential, with the first study slated to start in Q1 2025. Financially, the company raised $12.7 million through its equity line of credit and $7.1 million from warrant exercises, securing its runway to enter Phase 3 trials. Annovis also strengthened its intellectual property with new patents for buntanetap combination therapies and expanded its team with the appointment of Senior Clinical Scientist Dr. Matthew Peterson to support trial quality and completion.
NOTE TO INVESTORS: The latest news and updates relating to ANVS are available in the company’s newsroom at https://nnw.fm/ANVS
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)Anv Sec Group Inc. (ANVS) Stock Research Links
Scroll down for more posts ▼